financetom
Business
financetom
/
Business
/
Devonian Health Group Closes Non-Brokered Private Placement; Down Nearly 7%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Devonian Health Group Closes Non-Brokered Private Placement; Down Nearly 7%
Mar 14, 2024 10:24 AM

01:14 PM EDT, 03/14/2024 (MT Newswires) -- Devonian Health Group Inc. ( DVHGF ) said Thursday that it has raised gross proceeds of $223,800 by completing its non-brokered private placement.

The company's stock dropped 6.8% on last look on Thursday.

The offering comprised about 1.5 million units at $0.15 apiece. Each unit consists of one subordinate voting share and one share purchase warrant.

Each warrant allows the holder to buy one share at an exercise price of $0.20 apiece for 24 months from the date of issuance. The offering follows the recent $2.2 million term loan term loan previously announced.

The company plans to use the proceeds mainly to fund working capital relating to general and administrative expenses. The proceeds will also be used to settle certain debts of the company.

Devonian Health Group ( DVHGF ) is a late-stage botanical pharmaceutical company.

Price: 0.21, Change: -0.02, Percent Change: -6.82

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Edgewise's Phase 2 Trial of Sevasemten to Treat Becker Muscular Dystrophy Meets Primary Endpoint; Shares Up 22% Pre-Bell
Edgewise's Phase 2 Trial of Sevasemten to Treat Becker Muscular Dystrophy Meets Primary Endpoint; Shares Up 22% Pre-Bell
Dec 16, 2024
07:55 AM EST, 12/16/2024 (MT Newswires) -- Edgewise Therapeutics ( EWTX ) said Monday that a phase 2 trial of sevasemten to treat patients with Becker muscular dystrophy met its primary endpoint of change from baseline in creatine kinase. The biopharmaceutical company also said the key secondary endpoint of function demonstrated an improving trend over time in the sevasemten-treated group....
Barrick Gold May Suspend Mali Operations Amid Dispute with Government
Barrick Gold May Suspend Mali Operations Amid Dispute with Government
Dec 16, 2024
07:54 AM EST, 12/16/2024 (MT Newswires) -- Barrick Gold ( GOLD ) said Monday that it will be compelled to suspend the Loulo-Gounkoto operation in Mali if shipments remain suspended amid a dispute with the government. The miner said it has been unsuccessful in reaching a final resolution with the government despite numerous good-faith attempts to negotiate and a willingness...
KBR Awarded $445 Million Contract to Support US Joint Mission Environment Test Capability Program
KBR Awarded $445 Million Contract to Support US Joint Mission Environment Test Capability Program
Dec 16, 2024
07:58 AM EST, 12/16/2024 (MT Newswires) -- KBR (KBR) said Monday that the US Defense Department has awarded the company a $445 million cost-plus-fixed-fee contract to support the Joint Mission Environment Test Capability program. Under the terms of the contract, KBR said it will research, assess and address unique test and experimentation requirements to enhance JMETC's capabilities and integrate work...
Goldman Sachs Asset Management Reportedly to Acquire Synthon for $2.1 Billion
Goldman Sachs Asset Management Reportedly to Acquire Synthon for $2.1 Billion
Dec 16, 2024
07:56 AM EST, 12/16/2024 (MT Newswires) -- Goldman Sachs' ( GS ) investment arm, Goldman Sachs Asset Management, has agreed to acquire drugmaker Synthon from private equity group BC Partners for more than 2 billion euro ($2.10 billion), the Financial Times reported Monday, citing people familiar with the matter. Goldman Sachs ( GS ) did not immediately respond to a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved